Title : Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.

Pub. Date : 2018 May

PMID : 29434279






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although the first-in-class JAK3 inhibitor tofacitinib blocks JAK3 activity in NKTL both in vitro and in vivo, its clinical utilization in cancer therapy has been limited by the pan-JAK inhibition activity. tofacitinib Janus kinase 3 Homo sapiens
2 Although the first-in-class JAK3 inhibitor tofacitinib blocks JAK3 activity in NKTL both in vitro and in vivo, its clinical utilization in cancer therapy has been limited by the pan-JAK inhibition activity. tofacitinib Janus kinase 3 Homo sapiens